Back to results
US 2022/0033820 A1Published application
Compositions for treating muscular dystrophy
AssigneeSarepta Therapeutics, Inc.
InventorEdward M. KAYE
Life of this patent
Estimating the term…
Abstract
Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Claims4
1-23. (canceled)
An antisense oligonucleotide of 23 nucleotides in length, comprising the nucleotide sequence of SEQ ID NO:
- 112, wherein the uracil bases are optionally thymine bases.
Dependencies are inferred from the claim text.